drugset

drugset / Trial / NCT05497843

Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

NCT05497843 ↗

Phase 2 Completed 40 enrolled Chipscreen Biosciences, Ltd.

NaSequentialOpen-labelTreatment

Summary

This is a Phase 2, single-arm, open-label study in patients with advanced or unresectable soft tissue sarcoma.

Timeline

Start: 2022-08-25
Primary completion: 2025-01-03
Completion: 2025-01-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	IBCASERTIB	Small molecule	50 mg	Oral

Indications